top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

John Danhakl Biography and Net Worth

Director of IQVIA

John G. Danhakl has served as a director of IQVIA since October 2016. Prior to this, Mr. Danhakl served as a Director of IMS Health from February 2010 until October 2016. He is a Managing Partner at LGP, which he joined in 1995. Previously, Mr. Danhakl was a Managing Director of Donaldson, Lufkin & Jenrette Securities Corporation, which he joined in 1990. From 1985 until 1990, he was a Vice President in corporate finance at Drexel Burnham Lambert, Inc. Mr. Danhakl currently serves on the boards of directors of the following publicly traded companies: Savers, Inc., J. Crew Group, Inc., Petco Animal Supplies, Inc. and Arden Group, Inc. He previously served as a director of Big 5 Sporting Goods Corporation, Communications & Power Industries, Diamond Triumph Auto Glass, Inc., Liberty Group Publishing, Inc., MEMC Electronic Materials, Inc., Phoenix Scientific, Inc., Rite Aid Corporation, VCA Antech, Inc., Air Lease Corporation and The Neiman Marcus Group, Inc. Mr. Danhakl holds a bachelor of arts in Economics from the University of California at Berkeley, and an MBA from Harvard Business School. Mr. Danhakl serves as a member of the Nominating and Governance Committee.

How do I contact John G. Danhakl?: The corporate mailing address for Mr. Danhakl and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on John G. Danhakl's contact information.
Has John G. Danhakl been buying or selling shares of IQVIA?: John G. Danhakl has not been actively trading shares of IQVIA over the course of the past ninety days. Most recently, on Wednesday, December 22nd, John G. Danhakl bought 10,000 shares of IQVIA stock. The stock was acquired at an average cost of $272.93 per share, with a total value of $2,729,300.00. Learn More on John G. Danhakl's trading history.
Who are IQVIA's active insiders?: IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), and Eric Sherbet (Insider). Learn More on IQVIA's active insiders.
Are insiders buying or selling shares of IQVIA?: In the last year, insiders at the medical research company sold shares 7 times. They sold a total of 87,540 shares worth more than $20,013,870.89. The most recent insider tranaction occured on March, 1st when insider Ari Bousbib sold 31,678 shares worth more than $7,936,289.34. Insiders at IQVIA own 1.6% of the company. Learn More about insider trades at IQVIA.
Information on this page was last updated on 3/1/2024.

John G. Danhakl Insider Trading History at IQVIA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/22/2021	Buy	10,000	$272.93	$2,729,300.00
12/23/2020	Buy	63,451	$176.95	$11,227,654.45
9/12/2018	Sell	370,470	$124.83	$46,245,770.10
9/7/2018	Sell	221,900	$126.63	$28,099,197.00
5/30/2017	Sell	761,143	$84.01	$63,943,623.43

John G. Danhakl Buying and Selling Activity at IQVIA

IQVIA Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Today's Range

Now: $240.84

$237.70

$244.27

50 Day Range

MA: $245.50

$227.17

$259.15

2 Week Range

Now: $240.84

$167.42

$261.73

Volume

1,492,788 shs

Average Volume

972,338 shs

Market Capitalization

$43.71 billion

P/E Ratio

33.04

Dividend Yield

N/A

Beta

1.5